An expanded access record providing Diiodothyropropionic acid (DITPA) in Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, sponsored by Roy E. Weiss, M.D.. Available at 1 site in United States. Open to male participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Roy E. Weiss, M.D. · Expanded access
Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.
This is the only study on the registry with Roy E. Weiss, M.D. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Parental decision to terminate the pregnancy.
Current use of sympathomimetic therapy. Anticoagulant therapy. Use of Cytochrome P450 2C9 (CYP2C9) inhibitors with a narrow therapeutic index.
Drug Administration
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allan-Herndon-Dudley syndrome